852820-97-4 Usage
Description
(3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidine-5-yl]-3,5-dihydroxyhept-6-enoic acid isopropylamine is a complex organic compound with a specific stereochemistry denoted by the (3R,5S,6E) configuration. It consists of a 3,5-dihydroxyhept-6-enoic acid backbone, which is combined with isopropylamine and a pyrimidine-5-yl group. Additionally, it features a fluorophenyl moiety and an N-methylmethanesulfonamido functional group. This intricate structure suggests potential pharmaceutical applications, and understanding its properties could be valuable for drug development and scientific research.
Uses
Used in Pharmaceutical Industry:
(3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidine-5-yl]-3,5-dihydroxyhept-6-enoic acid isopropylamine is used as a pharmaceutical compound for its potential therapeutic effects. The specific structure and functional groups present in the molecule may contribute to its interaction with biological targets, such as enzymes or receptors, which could lead to the modulation of various biological processes and the treatment of certain diseases.
Used in Drug Development Research:
In the field of drug development research, this compound serves as a valuable subject for studying the relationship between chemical structure and biological activity. Its unique features, such as the fluorophenyl moiety and the N-methylmethanesulfonamido group, may provide insights into the design of new drugs with improved efficacy and selectivity.
Used in Chemical Synthesis:
(3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidine-5-yl]-3,5-dihydroxyhept-6-enoic acid isopropylamine can also be used as a starting material or intermediate in the synthesis of other complex organic molecules. Its versatile structure allows for further chemical modifications, which can lead to the creation of novel compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 852820-97-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,2,8,2 and 0 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 852820-97:
(8*8)+(7*5)+(6*2)+(5*8)+(4*2)+(3*0)+(2*9)+(1*7)=184
184 % 10 = 4
So 852820-97-4 is a valid CAS Registry Number.
852820-97-4Relevant articles and documents
Preparation process of rosuvastatin calcium preparation
-
, (2018/10/11)
The invention provides a preparation process of a rosuvastatin calcium preparation, and belongs to the technical field of pharmaceutical preparations. With (3R)-tert-butyldimethylsiloxy-5-oxy-6-triphenylphosphoranylidene methyl caproate and 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl amino)pyridine-5-formaldehyde as initial raw materials, wittig reaction, deprotection reaction, chiral reduction reaction, hydrolysis reaction and purification are carried out so as to obtain a rosuvastatin calcium crude drug; then the rosuvastatin calcium crude drug is uniformly mixed with a diluent, a disintegrating agent, a stabilizing agent and a lubricant so as to obtain a mixture, and then the mixture is tabletted so as to obtain the rosuvastatin calcium preparation. The preparation process of the rosuvastatin calcium preparation disclosed by the invention has the advantages of simple operation, high yield, low cost and stable quality.
PROCESS FOR PREPARING AMORPHOUS ROSUVASTATIN CALCIUM FREE OF IMPURITIES
-
Page/Page column 13-14; 15, (2008/06/13)
A pure amorphous form of rosuvastatin calcium having purity of more than 99.5%, preferably a purity of more than 99.8%, more preferably a purity of more than 99.9% as determined by HPLC area percentage, and free from any traces of alkali metal impurities is disclosed. A process of preparing said pure amorphous form of rosuvastatin calcium is disclosed, which comprises hydrolysis of C1-C5 alkyl esters of rosuvastatin, preferably terf-butyl ester of rosuvastatin, with an organic nitrogen base, e.g. guanidines, amidines, amines and quaternary ammonium hydroxides, in the presence of water, optionally containing aprotic solvent, following the conversion of thus obtained rosuvastain salt with a source of calcium to desired rosuvastatin calcium, which is then isolated. An alternative process is disclosed, which comprises the conversion of numerous novel ammonium salts of rosuvastatin, preferably tert-octylammonium salt of rosuvastatin, with the source of calcium to desired commercial rosuvastatin calcium.. Rosuvastatin calcium is HMG CoA reductase, useful in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis.
